Enoxaparin Versus Unfractionated Heparin in PCI

This study has been completed.
Sponsor:
Information provided by:
Triemli Hospital
ClinicalTrials.gov Identifier:
NCT00439855
First received: February 23, 2007
Last updated: NA
Last verified: February 2007
History: No changes posted

February 23, 2007
February 23, 2007
September 2003
Not Provided
Quadruple endpoint: death, MI, urgent TVR, major bleeding
Same as current
No Changes Posted
major bleeding, minor bleeding, thrombocytopenia
Same as current
Not Provided
Not Provided
 
Enoxaparin Versus Unfractionated Heparin in PCI
Enoxaparin Versus Unfractionated Heparin in PCI

Enoxaparin 0.75mg/kg BW is not inferior to weight adjusted unfractionated heparin as anticoagulation for PCI

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Coronary Artery Disease
  • Drug: Enoxaparin i.v.
  • Drug: unfractionated heparin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2100
February 2006
Not Provided

Inclusion Criteria:

  • PCI for stable ischemia or ACS

Exclusion Criteria:

  • Cardiogenic shock,
  • Pretreatment with study drugs,
  • Lack of informed consent
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Switzerland
 
NCT00439855
ZEUS
Not Provided
Not Provided
Triemli Hospital
Not Provided
Principal Investigator: osmund bertel, MD Division of Cardiology Triemli Hospital Zurich
Triemli Hospital
February 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP